# Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study

> **NCT07486869** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Miami** · enrollment: 5 (estimated)

## Conditions studied

- Dermatomyositis
- Dermatomyositis Sine Myositis
- Dermatomyositis With Myopathy
- Dermatomyositis With Respiratory Involvement
- Dermatomyositis With Organ Involvement
- Interstitial Lung Disease
- Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)

## Interventions

- **DRUG:** Emapalumab

## Key facts

- **NCT ID:** NCT07486869
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07486869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07486869, "Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07486869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*